Status:
COMPLETED
Collection of Tissue Samples for Study of Multidrug Resistance
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Breast Carcinoma
Breast Cancer
Eligibility:
All Genders
18-99 years
Brief Summary
Background: Resistance to cancer chemotherapy develops in patients, rendering certain treatments ineffective. Despite much research, the prevailing cause of drug resistance is not known. One mechani...
Detailed Description
Background: Ultimately, patients who succumb to cancer do so because of drug resistance. Mechanisms of drug resistance have been explored in the laboratory and in clinical samples for some time, yet ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Any patients entered on approved trials of cancer therapeutics at Children's Hospital of Pittsburgh, Herlev Hospital, and the University of Copenhagen outside of the intramural NCI are eligible for inclusion, provided that they have consented to tumor studies in the original consent forms.
- EXCLUSION CRITERIA:
- None anticipated at this time.
Exclusion
Key Trial Info
Start Date :
December 19 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 8 2018
Estimated Enrollment :
325 Patients enrolled
Trial Details
Trial ID
NCT00880503
Start Date
December 19 2003
End Date
February 8 2018
Last Update
December 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Childrens Hospital, Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213-2583